Healthcare Wrap: Opthea Collapses, Control Bionics and Biome Surge

Opthea (ASX:OPT) dominated the week for the wrong reason, plunging 97.50% after trading resumed and investors adjusted to a much smaller story built around OPT-302 for the rare lung disease LAM. Control Bionics (ASX:CBL) went the other way, rising 41.07% as buyers responded to new Medicare and German insurance coverage, plus fresh US distribution deals. Biome Australia (ASX:BIO) added 26.88% after signing an onshore manufacturing deal that could lift profit on each sale and reduce the cash tied up in inventory.

Commercial wins drew the strongest buying

Pro Medicus (ASX:PME) climbed 25.24% after a fresh $16 million US cloud imaging contract and a separate $16 million renewal with Ohio State Medical Center. Investors liked the simple message. Large hospitals are still signing long contracts, and existing customers are renewing on better terms. Vitrafy Life Sciences (ASX:VFY) rose 25.48% after partnering with Vitalant to tackle a looming gap in US blood storage technology. Optiscan Imaging (ASX:OIL) gained 19.15% as its Mayo Clinic robotic surgery work hit a two-year milestone and its breast cancer imaging study reached halfway. Several smaller names also moved on expansion news that investors could easily understand. ReNerve (ASX:RNV) signed new distribution deals covering Malaysia, Hong Kong, Macau and the Greater Bay Area. Memphasys (ASX:MEM) advanced into Vietnam's IVF market with a two-year Felix deal worth $530,000, subject to local approval. Micro-X (ASX:MX1) edged up 2.44% after producing first human images from its carbon nanotube head CT scanner, a step that matters because it shows the machine works in a real patient setting, not just in the lab.

Fresh cash stayed central

Capital raising remained a big part of the healthcare tape. EBR Systems (ASX:EBR) raised $106.4 million in an institutional placement and entitlement offer, while also winning an important US Medicare review step for its WiSE pacing device. Even so, the stock fell 10.79%. That often happens when a company raises money at a discount. Existing holders worry about dilution, which means their slice of the company becomes smaller. Pacific Edge (ASX:PEB) handled that balance better, gaining 11.11% after raising NZ$36.1 million in an oversubscribed offer backed mostly by existing shareholders. Paradigm Biopharma (ASX:PAR) still fell 12.12% despite an oversubscribed share purchase plan, while Racura Oncology (ASX:RAC) rose 4.65% after adding to its Phase 3 war chest. Microba Life Sciences (ASX:MAP) went into suspension ahead of a capital raise and a break-even update, so investors will soon get a clearer read on how much cash it needs and how quickly losses may narrow.

Deals and restructures changed the shape of the sector

Little Green Pharma (ASX:LGP) finished its merger with Cannatrek, creating a larger medicinal cannabis group with operations that stretch from growing product to running clinics and digital health services. Green Cross Health (NZX:GXH) agreed to sell The Doctors medical division for NZ$270 million so it can focus on pharmacy. Ryman Healthcare (NZX:RYM) reported much stronger cash flow and positive free cash flow for the first time in more than a decade, then set out a slower and more sustainable growth plan. In plain terms, it is choosing to build less aggressively and protect cash. Promisia Healthcare (NZX:PHL) posted a 58% jump in underlying EBITDAF to $6.6 million and introduced a dividend policy linked to operating free cash flow. That matters because it ties future payouts to cash actually generated by the business, not accounting profit. ParagonCare (ASX:PGC) also steadied sentiment with guidance that held despite cost pressure, and a possible recovery from Infinity Group receivables that had already been fully provided for.

Clinical and regulatory news was mixed

4DMedical (ASX:4DX) had one of the busiest weeks. It bought Austrian imaging group contextflow to gain a ready-made base in Europe and launched the CLEAR program to support wider US use of its lung imaging tool in suspected pulmonary embolism. Yet the share price finished the week flat, and after re-opening the stock drifted lower. Early gains evaporated as investors weighed the cost of expansion against the time needed to turn new markets into sales. Austco Healthcare (ASX:AHC) gave upbeat guidance for revenue and profit growth, helped by a US rollout across 180 hospitals, but the stock still dropped 26.23%. After re-opening, it fell further. That suggests investors wanted more than guidance. They may have worried about the lower margin forecast and the amount of spending needed to deliver the rollout. Chimeric Therapeutics (ASX:CHM) reported encouraging early cancer trial data, with 82% of evaluable patients showing stable disease, but the stock lost 18.00%. Early trial results can attract interest, but they also leave big questions on later-stage proof, cost and timelines. Elsewhere, Imagion Biosystems (ASX:IBX) cleared an FDA hurdle for a breast cancer imaging trial, Cynata Therapeutics (ASX:CYP) won European support for its child trial plan in graft versus host disease, and Entropy Neurodynamics (ASX:ENP) completed dosing in the first cohort of its binge eating disorder study. In each case, the science moved forward. But for share prices, the next proof point still matters more: patient recruitment, safety reviews, later-stage data or a path to sales.